The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)
Study Details
Study Description
Brief Summary
The purpose of this study is to investigate the Safety and Efficacy of Cilostazol in slowing down the progression of peripheral arterial disease (PAD) in ischemic stroke patients with PAD in Taiwan.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
One thousand patients will be randomized to take cilostazol (500 patients) or placebo (500 patients) in parallel groups. Patients will be screened and evaluated on Visits 1 to assess their eligibility prior to randomization. The treatment period (Visit 1-6) will last 12 months and the patient will receive initial and follow-up evaluation (section 4.5) including history and physical examinations, and baseline and end of treatment ABI and carotid IMT assessments. Vascular events and death as well as adverse events including bleeding complications will also be recorded at intervals as detailed in section 4.5.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Cilostazol Pletaal® (Cilostazol) 100 mg, bid p.o. |
Drug: Cilostazol
100 mg, bid p.o.
Other Names:
|
| Placebo Comparator: placebo Placebo 1 tablet, bid p.o. |
Other: placebo
1 tablet, bid
|
Outcome Measures
Primary Outcome Measures
- The primary endpoint for this study is slowdown of PAD progression based on ABI. [2 years]
Secondary Outcome Measures
- Carotid intima-media thickness [2 years]
Carotid intima-media thickness. Vascular events, including recurrent stroke, myocardial infarction, unstable angina,other vascular events, and all death. Safety, including major bleeding events, hemorrhagic stroke, any death.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female patients, age ≧50 years; for female patients, postmenopausal (defined as at least 2 years without menses) has to be confirmed.
-
Ischemic stroke or transient ischemic attack patients who have been taking aspirin 100 mg, QD
-
Neurologically and clinically stable at inclusion
-
PAD (i.e. ankle-brachial index or ABI <1.0)
Exclusion Criteria:
-
Patients unable to give informed consent
-
Patients with history of any type of hemorrhagic stroke (intracerebral hemorrhage,subarachnoid hemorrhage, or others)
-
Modified Rankin Scale >4
-
Patients with history of dementia requiring institutional care
-
Known brain tumor
-
Known anemia (defined as hemoglobin <10.0 g/dL)
-
Known thrombocytopenia (defined as platelet count below 100,000/cm3)
-
AST or ALT > 3 x Upper Normal Limit
-
Calculated creatinine clearance < 30 ml/min according to the Copckroft formula)
-
Known hemostasis or coagulation disorder
-
Congestive heart failure, defined as a previous definitive diagnosis, or present symptoms of at least Category II of the NYHA classification system for CHF
-
Revascularization of the lower limb arteries including bypass surgery, endovascular procedures
-
Symptomatic PAD requiring treatment with cilostazol
-
Known stenosis of the upper limb arteries that may affect the documentation of ABI
-
Patients with known hypersensitivity to cilostazol
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- China Medical University Hospital
- National Taiwan University Hospital
- Shin Kong Wu Ho-Su Memorial Hospital
- Tri-Service General Hospital
- Far Eastern Memorial Hospital
- Changhua Christian Hospital
- Chi Mei Medical Hospital
- National Cheng-Kung University Hospital
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- E-DA Hospital
- Mackay Memorial Hospital
- Cathay General Hospital
- En Chu Kong Hospital
- Kuang Tien General Hospital
- Chung Shan Medical University
- Taipei Veterans General Hospital, Taiwan
Investigators
- Principal Investigator: Chung Y. Hsu, MD. Ph.D., China Medical University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DMR99-IRB-137